Can a multivitamin supplement reduce menopausal symptoms and improve brain function during perimenopause?
| ISRCTN | ISRCTN10942256 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10942256 |
| Sponsor | University of East Anglia |
| Funders | Heights (Braincare Limited), University of East Anglia |
- Submission date
- 06/07/2026
- Registration date
- 09/07/2026
- Last edited
- 09/07/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
Around 13 million women in the UK are going through or have gone through the menopause. Many experience symptoms such as hot flushes, night sweats, poor sleep, low mood, and difficulty concentrating, often called 'brain fog'. Currently, hormone replacement therapy (HRT) is the main recommended treatment, but it is not suitable or desirable for all women. There is a real need for safe, accessible alternatives. This study aims to investigate whether a commercially available multi-nutrient supplement called Vitals+ (Heights, London), which contains vitamins, minerals, omega-3 fatty acids, and a plant extract, can help to improve brain function, mood, cognition, and menopausal symptoms in a woman going through the menopause transition.
Who can participate?
We are looking for one healthy woman aged 45–55 years who has been experiencing perimenopausal symptoms for at least 2 years. She must not currently be taking HRT or any nutritional supplements and must be willing and able to attend regular visits at the University of East Anglia in Norwich.
What does the study involve?
The study lasts approximately 7 months and involves 32 visits to the UEA brain imaging centre, each lasting up to 1 hour. During each visit, the participant will have a brain MRI scan (30 minutes), a blood pressure measurement, and will complete a short mood questionnaire. She will also provide a small finger-prick blood sample. Each week, she will complete online cognitive and symptom questionnaires at home. For 12 weeks, she will take two capsules of the Vitals+ supplement each day. There is an 8-week monitoring period before and after taking the supplement.
What are the possible benefits and risks of participating?
There are no anticipated safety risks from the supplement, which is already on sale to the public. MRI is a non-invasive technique with no known side effects, though some people find the scanner noisy or slightly claustrophobic. Minor discomfort may occur from finger-prick blood sampling. Potential benefits include improvements in mood, concentration, and menopausal symptoms, although this cannot be guaranteed.
Where is the study run from?
The study is run from the UEA Wellcome-Wolfson Brain Imaging Centre (UWWBIC) at the University of East Anglia, Norwich (UK)
When is the study starting and how long is it expected to run for?
January 2026 to July 2026
Who is funding the study?
The study is funded by Heights (Braincare Limited), who also supply the Vitals+ supplement. Some staff and MRI costs are provided by the University of East Anglia.
Who is the main contact?
Prof. Anne-Marie Minihane, A.Minihane@uea.ac.uk
Contact information
Principal investigator, Scientific, Public
BCRE, Rosalind Franklin Road
University of East Anglia (UEA)
Norwich
NR4 7UQ
United Kingdom
| Phone | +44 (0)1603 592389 |
|---|---|
| A.Minihane@uea.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | N/A: single arm study |
| Masking | Open (masking not used) |
| Control | Uncontrolled |
| Assignment | Single |
| Purpose | Treatment |
| Scientific title | The effect of a multivitamin supplement (Vitals+) on brain function, cognition, mood, and vasomotor symptoms in a perimenopausal woman: a proof-of-concept n = 1 deep-phenotyping study |
| Study acronym | VITAL-BRAIN |
| Study objectives | |
| Ethics approval(s) |
Approved 01/09/2025, University of East Anglia Faculty of Medicine and Health Sciences Research Ethics Subcommittee (Research and Innovation Services, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom; +44 (0)1603 456161; fmh.ethics@uea.ac.uk), ref: ETH2425-2520 |
| Health condition(s) or problem(s) studied | Menopause |
| Intervention | The participant receives Vitals+, a commercially available multivitamin supplement (Heights, Braincare Limited, London), at a dose of two capsules per day for 12 weeks. The supplement contains 12 vitamins (thiamine/B1, riboflavin/B2, niacin/B3, pantothenic acid/B5, B6, biotin/B7, folate/B9 as 5-MTHF, B12 as methylcobalamin, vitamin A, vitamin C, vitamin D3, and vitamin E), 5 minerals (iron, zinc, selenium, chromium, and iodine), two omega-3 fatty acids from algae oil (EPA and DHA), and bilberry extract (36% anthocyanins). The supplement is an oral capsule. The total study duration is 28 weeks (7 months): an 8-week pre-intervention baseline assessment phase, followed by the 12-week supplementation period, with an 8-week post-intervention assessment phase. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 31/07/2026 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 45 Years |
| Upper age limit | 55 Years |
| Sex | Female |
| Target sample size at registration | 1 |
| Total final enrolment | 1 |
| Key inclusion criteria | 1. Female aged 45–55 years 2. Perimenopausal (as defined by NICE Menopause guidelines 2024) for at least 2 years 3. Free from major neuropsychiatric conditions (e.g., depression), neurological conditions (e.g. multiple sclerosis), and gynaecological conditions (e.g., endometriosis) 4. Able to provide informed consent 5. Willing to undergo the full study protocol, including 32 clinic visits, MRI scanning, and biological sample collection |
| Key exclusion criteria | 1. Currently taking hormone replacement therapy (HRT) 2. Use of any nutritional supplements within the last 3 months 3. Consumption of more than 1 portion of oily fish per month AND red blood cell omega-3 index >6% 4. Consumption of more than 4 portions of fruit and vegetables per day 5. Consumption of more than 4 portions of B-vitamin fortified foods per week 6. Contraindication to MRI (e.g. metallic implants, pacemaker, cochlear implant, severe claustrophobia) 7. Postmenopausal (no menstrual cycle for ≥12 months) |
| Date of first enrolment | 20/01/2026 |
| Date of final enrolment | 20/01/2026 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
University of East Anglia
Norwich Research Park
Earlham Road
Norwich
NR4 7TJ
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
09/07/2026: Study's existence confirmed by the University of East Anglia Faculty of Medicine and Health Sciences Research Ethics Subcommittee.